FRNM
NASD Freenome, Inc.$12.64 ↑ +0.00 (+0.00%) Trading Up from the previous close of $12.64, $0.73 below the day’s high of $13.37
- YTD change
- -2.84%
- vs 20-day SMA
- -20.35%
- vs 200-day SMA
- N/A
Price ranges
Price & Performance
-0.37 (-2.84%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 27.8% away from all-time highs of $17.50
- FRNM is down 3% since the beginning of the year
- FRNM is down 3% over the past 12 months
- FRNM is down 16% over the past 1 month
- 43% of all FRNM investors are betting against FRNM
FRNM reads poor: the 12-month move is -2.8%.
- Previous minute
- +$0.00
- Last hour
- -$0.16
- Last 5 days
- -24.90%
- vs 8-day SMA
- -19.74%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Freenome, Inc. operates as an early detection company, which engages in the development of blood-based screening tests to detect cancer. Its proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. The company was founded by Riley Ennis in 2014 and is headquartered in Brisbane, CA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.